Relationship between the pharmacokinetics of Levosimendan and its effects on cardiovascular system

Current Drug Metabolism

Volumn 10, Issue 2, 2009, Pages 95-103

  Antoniades, Charalambos ^a,b   Antonopoulos, Alexios S ^a   Tousoulis, Dimitris ^a   Bakogiannis, Constantinos ^a   Stefanadi, Elli ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Ca2+ sensitizers; Heart failure; Levosimendan; Metabolism; Pharmacokinetics

Indexed keywords

ACYLTRANSFERASE; CALCIUM ION; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; INOTROPIC AGENT; LEVOSIMENDAN; MILRINONE; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; NITRATE; OR 1855; PLACEBO; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; CALCIUM BINDING; CALCIUM SIGNALING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; CORONARY ARTERY DILATATION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG ACETYLATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SULFATION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART PROTECTION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; INOTROPISM; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIVER FAILURE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PHARMACODYNAMICS; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; STEADY STATE; TACHYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VASODILATATION;

ANIMALS; CALCIUM; CARDIOTONIC AGENTS; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; HYDRAZONES; POTASSIUM CHANNELS; PYRIDAZINES; VASODILATION;

EID: 65549104964     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009787522142     Document Type: Review

References (66)

1. 2+ sensitizers rescue patients from chronic congestive heart failure? Br. J. Pharmacol., 2007, 150(7), 826-8.
2. Endoh, M.; Hori, M. Acute heart failure: inotropic agents and their clinical uses. Expert Opin. Pharmacother., 2006, 7(16), 2179-202.
3. Antoniades, C.; Tousoulis, D.; Koumallos, N.; Marinou, K.; Stefanadis, C. Levosimendan: beyond its simple inotropic effect in heart failure. Pharmacol. Ther., 2007, 114(2), 184-97.
4. Antila, S.; Sundberg, S.; Lehtonen, L.A. Clinical pharmacology of levosimendan. Clin. Pharmacokinet., 2007, 46(7), 535-52.
5. Toller, W.G.; Stranz, C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology, 2006, 104(3), 556-69.
6. Koumallos, N.; Antoniades, C.; Tousoulis, D.; Shirodaria, C.; Stefanadis, C. Levosimendan: a novel agent in heart failure. Recent Patents Cardiovasc. Drug. Discov., 2006, 1(2), 185-91.
7. Ajiro, Y.; Hagiwara, N.; Katsube, Y.; Sperelakis, N.; Kasanuki, H. Levosimendan increases L-type Ca(2+) current via phosphodiesterase-3 inhibition in human cardiac myocytes. Eur. J. Pharmacol., 2002, 435(1), 27-33.
8. Yokoshiki, H.; Katsube, Y.; Sunagawa, M.; Sperelakis, N. The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. J. Pharmacol. Exp. Ther., 1997, 283(1), 375-83.
9. Hasenfuss, G.; Pieske, B.; Castell, M.; Kretschmann, B.; Maier, L.S.; Just, H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation, 1998, 98(20), 2141-7.
10. Hasenfuss, G.; Pieske, B.; Kretschmann, B.; Holubarsch, C.; Alpert, N.R.; Just, H. Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics. J. Cardiovasc. Pharmacol., 1995, 26 Suppl 1, S45-51.
11. Szilagyi, S.; Pollesello, P.; Levijoki, J.; Kaheinen, P.; Haikala, H.; Edes, I.; Papp, Z. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur. J. Pharmacol., 2004, 486(1), 67-74.
12. Jonsson, E.N.; Antila, S.; McFadyen, L.; Lehtonen, L.; Karlsson, M.O. Population pharmacokinetics of levosimendan in patients with congestive heart failure. Br. J. Clin. Pharmacol., 2003, 55(6), 544-51.
13. Sandell, E.P.; Hayha, M.; Antila, S.; Heikkinen, P.; Ottoila, P.; Lehtonen, L.A.; Pentikainen, P.J. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J. Cardiovasc. Pharmacol., 1995, 26 (Suppl 1), S57-62.
14. Banfor, P.N.; Preusser, L.C.; Campbell, T.J.; Marsh, K.C.; Polakowski, J.S.; Reinhart, G.A.; Cox, B.F.; Fryer, R.M. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Am. J. Physiol. Heart Circ. Physiol., 2008, 294(1), H238-48.
15. Antila, S.; Kivikko, M.; Lehtonen, L.; Eha, J.; Heikkila, A.; Pohjanjousi, P.; Pentikainen, P.J. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan. Br. J. Clin. Pharmacol., 2004, 57(4), 412-5.
16. Antila, S.; Eha, J.; Heinpalu, M.; Lehtonen, L.; Loogna, I.; Mesikepp, A.; Planken, U.; Sandell, E.P. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril. Eur. J. Clin. Pharmacol., 1996, 49(6), 451-8.
17. Poder, P.; Eha, J.; Antila, S.; Heinpalu, M.; Planken, U.; Loogna, I.; Mesikepp, A.; Akkila, J.; Lehtonen, L. Pharmacodynamic interactions of levosimendan and felodipine in patients with coronary heart disease. Cardiovasc. Drugs Ther., 2003, 17(5-6), 451-8.
18. Kivikko, M.; Antila, S.; Eha, J.; Lehtonen, L.; Pentikainen, P.J. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int. J. Clin. Pharmacol. Ther., 2002, 40(10), 465-71.
19. Lilleberg, J.; Laine, M.; Palkama, T.; Kivikko, M.; Pohjanjousi, P.; Kupari, M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur. J. Heart Fail., 2007, 9(1), 75-82.
20. Kivikko, M.; Antila, S.; Eha, J.; Lehtonen, L.; Pentikainen, P.J. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J. Clin. Pharmacol., 2002, 42(1), 43-51.
21. Kivikko, M.; Lehtonen, L.; Colucci, W.S. Sustained hemodynamic effects of intravenous levosimendan. Circulation, 2003, 107(1), 81-6.
22. Puttonen, J.; Laine, T.; Ramela, M.; Hakkinen, S.; Zhang, W.; Pradhan, R.; Pentikainen, P.; Koskinen, M. Pharmacokinetics and excretion balance of OR-1896, a pharmacologically active metabolite of levosimendan, in healthy men. Eur. J. Pharm. Sci., 2007, 32(4-5), 271-7.
23. Antila, S.; Pesonen, U.; Lehtonen, L.; Tapanainen, P.; Nikkanen, H.; Vaahtera, K.; Scheinin, H. Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. Eur. J. Pharm. Sci., 2004, 23(3), 213-22.
24. Koskinen, M.; Puttonen, J.; Pykalainen, M.; Vuorela, A.; Lotta, T. Metabolism of OR-1896, a metabolite of levosimendan, in rats and humans. Xenobiotica, 2008, 38(2), 156-70.
25. Zhang, J.; Gage, E.M.; Ji, Q.C.; El-Shourbagy, T.A. A strategy for high-throughput analysis of levosimendan and its metabolites in human plasma samples using sequential negative and positive ionization liquid chromatography/tandem mass spectrometric detection. Rapid Commun. Mass. Spectrom., 2007, 21(14), 2169-76.
26. Puttonen, J.; Kantele, S.; Ruck, A.; Ramela, M.; Hakkinen, S.; Kivikko, M.; Pentikainen, P.J. Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment. J. Clin. Pharmacol., 2008, 48(4), 445-54.
27. Puttonen, J.; Kantele, S.; Kivikko, M.; Hakkinen, S.; Harjola, V.P.; Koskinen, P.; Pentikainen, P.J. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. Clin. Pharmacokinet., 2007, 46(3), 235-46.
28. Slawsky, M.T.; Colucci, W.S.; Gottlieb, S.S.; Greenberg, B.H.; Haeusslein, E.; Hare, J.; Hutchins, S.; Leier, C.V.; LeJemtel, T.H.; Loh, E.; Nicklas, J.; Ogilby, D.; Singh, B.N.; Smith, W. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation, 2000, 102(18), 2222-7.
29. Segreti, J.A.; Marsh, K.C.; Polakowski, J.S.; Fryer, R.M. Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1,4,5,6- tetrahydropyridazin-3-yl)phenyl)acetamid e], OR-1855 [(R)-6-(4- aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], dobutamine, and milrinone: comparative effects on peripheral resistance, cardiac output, dP/dt, pulse rate, and blood pressure. J. Pharmacol. Exp. Ther., 2008, 325(1), 331-40.
30. Parissis, J.T.; Paraskevaidis, I.; Bistola, V.; Farmakis, D.; Panou, F.; Kourea, K.; Nikolaou, M.; Filippatos, G.; Kremastinos, D. Effects of levosimendan on right ventricular function in patients with advanced heart failure. Am. J. Cardiol., 2006, 98(11), 1489-92.
31. Lilleberg, J.; Sundberg, S.; Nieminen, M.S. Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction. J. Cardiovasc. Pharmacol., 1995, 26 (Suppl 1), S63-9.
32. Poder, P.; Eha, J.; Sundberg, S.; Antila, S.; Heinpalu, M.; Loogna, I.; Planken, U.; Rantanen, S.; Lehtonen, L. Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study. J. Clin. Pharmacol., 2004, 44(10), 1143-50.
33. Poder, P.; Eha, J.; Sundberg, S.; Antila, S.; Heinpalu, M.; Loogna, I.; Planken, U.; Rantanen, S.; Lehtonen, L. Pharmacokinetic-pharmacodynamic interrelationships of intravenous and oral levosimendan in patients with severe congestive heart failure. Int. J. Clin. Pharmacol. Ther., 2003, 41(8), 365-73.
34. Valjakka-Koskela, R.; Hirvonen, J.; Monkkonen, J.; Kiesvaara, J.; Antila, S.; Lehtonen, L.; Urtti, A. Transdermal delivery of levosimendan. Eur. J. Pharm. Sci., 2000, 11(4), 343-50.
35. Dickstein, K.; Cohen-Solal, A.; Filippatos, G.; McMurray, J.J.; Ponikowski, P.; Poole-Wilson, P.A.; Stromberg, A.; van Veldhuisen, D.J.; Atar, D.; Hoes, A.W.; Keren, A.; Mebazaa, A.; Nieminen, M.; Priori, S.G.; Swedberg, K.; Vahanian, A.; Camm, J.; De Caterina, R.; Dean, V.; Dickstein, K.; Filippatos, G.; Funck-Brentano, C.; Hellemans, I.; Kristensen, S.D.; McGregor, K.; Sechtem, U.; Silber, S.; Tendera, M.; Widimsky, P.; Zamorano, J.L. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J., 2008, 29(19), 2388-442.
36. Parle, N.M.; Thomas, M.D.; Dembo, L.; Best, M.; Driscoll, G.O. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience. Heart Lung Circ., 2008, 17(3), 206-10.
37. Cleland, J.G.; Freemantle, N.; Coletta, A.P.; Clark, A.L. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur. J. Heart Fail., 2006, 8(1), 105-10.
38. Parissis, J.T.; Filippatos, G.; Farmakis, D.; Adamopoulos, S.; Paraskevaidis, I.; Kremastinos, D. Levosimendan for the treatment of acute heart failure syndromes. Expert. Opin. Pharmacother., 2005, 6(15), 2741-51.
39. Toivonen, L.; Viitasalo, M.; Sundberg, S.; Akkila, J.; Lehtonen, L. Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function. J. Cardiovasc. Pharmacol., 2000, 35(4), 664-9.
40. Lilleberg, J.; Ylonen, V.; Lehtonen, L.; Toivonen, L. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies. Scand. Cardiovasc. J., 2004, 38(2), 80-4.
41. Flevari, P.; Parissis, J.T.; Leftheriotis, D.; Panou, F.; Kourea, K.; Kremastinos, D.T. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. Am. J. Cardiol., 2006, 98(12), 1641-5.
42. Mebazaa, A.; Barraud, D.; Welschbillig, S. Randomized clinical trials with levosimendan. Am. J. Cardiol., 2005, 96(6A), 74G-9G.
43. Follath, F.; Cleland, J.G.; Just, H.; Papp, J.G.; Scholz, H.; Peuhkurinen, K.; Harjola, V.P.; Mitrovic, V.; Abdalla, M.; Sandell, E.P.; Lehtonen, L. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet, 2002, 360(9328), 196-202.
44. Moiseyev, V.S.; Poder, P.; Andrejevs, N.; Ruda, M.Y.; Golikov, A.P.; Lazebnik, L.B.; Kobalava, Z.D.; Lehtonen, L.A.; Laine, T.; Nieminen, M.S.; Lie, K.I. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur. Heart J., 2002, 23(18), 1422-32.
45. Delle Karth, G.; Buberl, A.; Geppert, A.; Neunteufl, T.; Huelsmann, M.; Kopp, C.; Nikfardjam, M.; Berger, R.; Heinz, G. Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiol. Scand., 2003, 47(10), 1251-6.
46. Nanas, J.N.; Papazoglou, P.; Tsagalou, E.P.; Ntalianis, A.; Tsolakis, E.; Terrovitis, J.V.; Kanakakis, J.; Nanas, S.N.; Alexopoulos, G.P.; Anastasiou-Nana, M.I. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone. Am. J. Cardiol., 2005, 95(6), 768-71.
47. Nanas, J.N.; Papazoglou, P.P.; Terrovitis, J.V.; Kanakakis, J.; Dalianis, A.; Tsolakis, E.; Tsagalou, E.P.; Agrios, N.; Christodoulou, K.; Anastasiou-Nana, M.I. Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone. Am. J. Cardiol., 2004, 94(10), 1329-32.
48. Antila, S.; Jarvinen, A.; Honkanen, T.; Lehtonen, L. Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosimendan and warfarin. Eur. J. Clin. Pharmacol., 2000, 56(9-10), 705-10.
49. Lehtonen, L.; Sundberg, S. The contractility enhancing effect of the calcium sensitiser levosimendan is not attenuated by carvedilol in healthy subjects. Eur. J. Clin. Pharmacol., 2002, 58(7), 449-52.
50. Harjola, V.P.; Oikarinen, L.; Toivonen, L.; Jurkko, R.; Puttonen, J.; Sarapohja, T.; Sundberg, S.; Nieminen, M.S. The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure. Int. J. Clin. Pharmacol. Ther., 2008, 46(8), 389-99.
51. Erdei, N.; Papp, Z.; Pollesello, P.; Edes, I.; Bagi, Z. The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles. Br. J. Pharmacol., 2006, 148(5), 696-702.
52. Yokoshiki, H.; Sperelakis, N. Vasodilating mechanisms of levosimendan. Cardiovasc. Drugs Ther., 2003, 17(2), 111-3.
53. Ikonomidis, I.; Parissis, J.T.; Paraskevaidis, I.; Kourea, K.; Bistola, V.; Lekakis, J.; Filippatos, G.; Kremastinos, D.T. Effects of levosimendan on coronary artery flow and cardiac performance in patients with advanced heart failure. Eur. J. Heart Fail., 2007, 9(12), 1172-7.
54. Yildiz, O. Vasodilating mechanisms of levosimendan: involvement of K+ channels. J. Pharmacol. Sci., 2007, 104(1), 1-5.
55. Gruhn, N.; Nielsen-Kudsk, J.E.; Theilgaard, S.; Bang, L.; Olesen, S.P.; Aldershvile, J. Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J. Cardiovasc. Pharmacol., 1998, 31(5), 741-9.
56. du Toit, E.F.; Genis, A.; Opie, L.H.; Pollesello, P.; Lochner, A. A role for the RISK pathway and K(ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart. Br. J. Pharmacol., 2008, 154(1), 41-50.
57. Yapici, D.; Altunkan, Z.; Ozeren, M.; Bilgin, E.; Balli, E.; Tamer, L.; Doruk, N.; Birbicer, H.; Apa, D.; Oral, U. Effects of levosimendan on myocardial ischaemia-reperfusion injury. Eur. J. Anaesthesiol., 2008, 25(1), 8-14.
58. Tritapepe, L.; De Santis, V.; Vitale, D.; Santulli, M.; Morelli, A.; Nofroni, I.; Puddu, P.E.; Singer, M.; Pietropaoli, P. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. Br. J. Anaesth., 2006, 96(6), 694-700.
59. Parissis, J.T.; Andreadou, I.; Bistola, V.; Paraskevaidis, I.; Filippatos, G.; Kremastinos, D.T. Novel biologic mechanisms of levosimendan and its effect on the failing heart. Expert. Opin. Investig. Drugs, 2008, 17(8), 1143-50.
60. Parissis, J.T.; Panou, F.; Farmakis, D.; Adamopoulos, S.; Filippatos, G.; Paraskevaidis, I.; Venetsanou, K.; Lekakis, J.; Kremastinos, D.T. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am. J. Cardiol., 2005, 96(3), 423-6.
61. Trikas, A.; Antoniades, C.; Latsios, G.; Vasiliadou, K.; Karamitros, I.; Tousoulis, D.; Tentolouris, C.; Stefanadis, C. Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. Eur. J. Heart Fail., 2006, 8(8), 804-9.
62. Parissis, J.T.; Karavidas, A.; Bistola, V.; Arapi, S.; Paraskevaidis, I.A.; Farmakis, D.; Korres, D.; Filippatos, G.; Matsakas, E.; Kremastinos, D.T. Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure. Atherosclerosis, 2008, 197(1), 278-82.
63. Parissis, J.T.; Adamopoulos, S.; Antoniades, C.; Kostakis, G.; Rigas, A.; Kyrzopoulos, S.; Iliodromitis, E.; Kremastinos, D. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. J. Am. Coll. Cardiol., 2004, 93(10), 1309.
64. Avgeropoulou, C.; Andreadou, I.; Markantonis-Kyroudis, S.; Demopoulou, M.; Missovoulos, P.; Androulakis, A.; Kallikazaros, I. The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur. J. Heart Fail., 2005, 7(5), 882-7.
65. Parissis, J.T.; Andreadou, I.; Markantonis, S.L.; Bistola, V.; Louka, A.; Pyriochou, A.; Paraskevaidis, I.; Filippatos, G.; Iliodromitis, E.K.; Kremastinos, D.T. Effects of Levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure. Atherosclerosis, 2007, 195(2), e210-5.
66. Mebazaa, A.; Nieminen, M.S.; Packer, M.; Cohen-Solal, A.; Kleber, F.X.; Pocock, S.J.; Thakkar, R.; Padley, R.J.; Poder, P.; Kivikko, M. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA, 2007, 297(17), 1883-91.